SeraNovo and Ildong Pharmaceutical to collaborate on research projects


SeraNovo BV (Leiden, the Netherlands) is pleased to announce the closing of a multi compound deal with Ildong Pharmaceutical (Seoul, South Korea), a pharmaceutical company engaged in the research and development of small molecules in the field of neuroscience and oncology.

Niall Hodgins, Chief Executive Officer of SeraNovo and Venture Challenge alumnus commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with Ildong.”

About SeraNovo: SeraNovo is a formulation technology provider enhancing the bioavailability of poorly soluble APIs. Our team is specialized in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. SeraNovo is a privately owned company located in Leiden, the Netherlands and as technology inventor owns all know-how and intellectual property. For more information, please visit

About Ildong Pharmaceuticals: ILDONG Company Profile: As a leading pharmaceutical company in South Korea, ILDONG Pharmaceutical Co., Ltd. has been dedicated and committed to the development and supply of superior pharmaceutical products that contribute to the health and well-being of people. ILDONG is steadfast in our vision of continuously growing with customers as a leading global company by providing solutions for disease prevention and developing new solutions for healthier and happier lives.




logo's of the two companies

‹ News overview